glp-1 drugs for parkinson's disease Popular obesity drug fails in hotly anticipated Alzheimer's trials | Science Ozempic-Like Drug Failed to Treat

Description

What were hearing from GLP-1 patients today is similarly specific, widespread, and unexpected

doi: 10.1016/j.phrs.2022.106550 24 SalcedoITweedieDLiYGreigNH

doi: 10.1186/s12933-021-01366-8 [DOI] [PMC free article] [PubMed] [Google Scholar] 199.Marso SP, Bain SC, Consoli A, et al

Double Incretin Receptor Knockout (DIRKO) Mice DIRKO mice have normal body weight and do not have improved glycaemic response following exogenous administration of GIP or the GLP-1R agonist exendin-4

TABLE 2 [i] GLP-1RAs glucagon-like peptide-1 receptor agonists, GIP/GLP-1RAs dual glucose-dependent insulinotropic polypeptide receptor agonists, SGLT2 inhibitors sodium-glucose cotransporter-2 inhibitors, ASA American Society of Anesthesiologists, ESAIC European Society of Anaesthesiology and Intensive Care